Evidence map›Paper›PMID 41142247›Full record

ArticleFrontiers in pharmacology2025

Topical prevention from high energy visible light-induced pigmentation by 2-mercaptonicotinoyl glycine, but not by ascorbic acid antioxidant: 2 randomized controlled trials.

Virginie Piffaut, Romain De Dormael, Jean-Philippe Belaidi, Laudine Bertrand, Thierry Passeron, Françoise Bernerd, Claire Marionnet

2 registry-linked trialsAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06937515 completednot on this map

Evaluation of the efficacy of an antimelanogenesis agent (melasyl) in different concentrations under part of visible light [400-450nm] exposures and under full visible light [400-700nm] exposures

TypeobservationalSponsorL'OrealRan2023 to 2023Enrolled31ConditionsVisible Light Exposure on Healthy Back SkinArmsCosmetic topical products
NCT06945393 completednot on this map

Evaluation of the efficacy of antipigmenting or depimenting agents under part of visible light [400-450nm] exposures

TypeobservationalSponsorL'OrealRan2021 to 2022Enrolled30ConditionsVisible Light Exposure on Healthy Back SkinArmsCosmetic topical products
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Virginie PiffautL'Oreal Research and Innovation, Aulnay-sous-Bois, France.
Romain De DormaelL'Oreal Research and Innovation, Aulnay-sous-Bois, France.
Jean-Philippe BelaidiL'Oreal Research and Innovation, Aulnay-sous-Bois, France.
Laudine BertrandL'Oreal Research and Innovation, Saint-Ouen, France.
Thierry PasseronDepartment of Dermatology, CHU Nice, Université Côte D'Azur, Nice, France.
Françoise BernerdL'Oreal Research and Innovation, Aulnay-sous-Bois, France.
Claire MarionnetL'Oreal Research and Innovation, Aulnay-sous-Bois, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hyperpigmentation and pigmentary disorders are major clinical consequences of sun exposure. While UV radiation is a known contributor, visible light (VL), particularly High Energy Visible (HEV) light (400-450 nm), also induces long-lasting pigmentation in melanocompetent individuals (Fitzpatrick Phototype III and above), and can worsen pigmentary disorders. Therefore, photoprotection in this wavelengths range is recommended to prevent worsening of hyperpigmentation issues. Efficient solutions rely on the use of pigments, absorbing and diffusing VL. However, tint and opacity of these products may limit their use by consumers and patients. The search for actives preventing VL-induced pigmentation is therefore of interest. This work aimed at assessing 2 non tinted biological actives to counteract HEV-induced pigmentation. Material and Methods: Two very potent inhibitors of UV-induced pigmentation, ascorbic acid 7% (powerful antioxidant) and 2-mercaptonicotinoyl glycine (2-MNG, 0.5 or 1%, melanogenesis inhibitor), were assessed in 2 controlled randomized clinical trials (registered under the identification numbers NCT06945393 and NCT06937515 on ClinicalTrials.gov), including in total, 58 individuals with Fitzpatrick Phototype III or IV. Delineated areas on the subjects back, topically treated or not by the product, were exposed to HEV once a day for 4 days. The product was applied before, during and 5 weeks after HEV exposure. Pigmentation was assessed using chromametry and visual scoring throughout the studies. Results: While ascorbic acid did not exhibit any efficacy versus its vehicle in limiting skin hyperpigmentation induced by HEV, the use of 2-MNG (0.5 or 1%) led to an early significant decrease in HEV-induced pigmentation, which was sustained until the end of the study, as evidenced by colorimetry and significantly scored by visual assessment. Moreover, a 2-MNG dose effect could be evidenced at early time points. Conclusion: 2-MNG represents an efficient and transparent alternative solution to pigments for the mitigation of HEV worsening of hyperpigmentation issues. This opens up perspectives for its use as a complement to UV protection afforded by sun filters.

Indexed as

high energy visible lighthyperpigmentationphotoprotectionpigmentary disorderspigmentationsolar lightsunscreenvisible light

Identifiers

PMID41142247
PMCPMC12546040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.